Lord Research Group
University of East Anglia (UEA)
Our research focuses on the design and synthesis of transition metal compounds and assessing their potential as anti-cancer drugs. We investigate a wide range of early and late transition metals incorporating variety of bidentate, tridentate and tetradentate ligands, and through in vitro screening, we provide structure activity relationships (SARs) for their ability to target cancerous cells. Our labs are equipped for state-of-the-art synthesis, and we have a wide range of cell viability assays available in-house through our Schools of Chemistry and Pharmacy. Not only are we using biochemical models to study our drugs within cancerous and healthy cells, we work along computational experts we are modelling biological systems and their interactions with our compounds.
Our aims are to investigate the modes of action of these drugs by using a wide range of analytical techniques. These include ICP-MS for cellular metal detection, whole-cell EPR to measure paramagnetic metals within cells, and live-cell imaging to visualise the uptake of fluorescent drugs within cells. Importantly for our research, we are addressing drug formulation problems and in vitro isomerisation of our drugs, in the hope to reduce pharmacological side-effects.